Literature DB >> 27986214

Management of Node-Positive and Oligometastatic Prostate Cancer.

James R Broughman1, Ronald C Chen2.   

Abstract

Historically, stage IV prostate cancer was considered incurable. Although node-positive and oligometastatic prostate cancers are both classified as stage IV, these likely represent distinct clinical groups, and some patients may be curable with aggressive multimodality treatments. There is a lack of randomized evidence, but retrospective studies suggest that radical prostatectomy or radiotherapy may improve survival in these patients. This is an area of great current research interest and prospective randomized trials are needed to help define the optimal treatments for these patients.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27986214     DOI: 10.1016/j.semradonc.2016.08.006

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  4 in total

Review 1.  Patients with Positive Lymph Nodes after Radical Prostatectomy and Pelvic Lymphadenectomy-Do We Know the Proper Way of Management?

Authors:  Bartosz Małkiewicz; Miłosz Knura; Małgorzata Łątkowska; Maximilian Kobylański; Krystian Nagi; Dawid Janczak; Joanna Chorbińska; Wojciech Krajewski; Jakub Karwacki; Tomasz Szydełko
Journal:  Cancers (Basel)       Date:  2022-05-08       Impact factor: 6.575

2.  99mTc-HDP bone scintigraphy and 18F-sodiumfluoride PET/CT in primary staging of patients with prostate cancer.

Authors:  Maurits Wondergem; Friso M van der Zant; Remco J J Knol; Anne Marij G Burgers; Siebe D Bos; Igle J de Jong; Jan Pruim
Journal:  World J Urol       Date:  2017-10-17       Impact factor: 4.226

3.  Intermediate-term outcome after PSMA-PET guided high-dose radiotherapy of recurrent high-risk prostate cancer patients.

Authors:  Sebastian Zschaeck; Peter Wust; Marcus Beck; Waldemar Wlodarczyk; David Kaul; Julian Rogasch; Volker Budach; Christian Furth; Pirus Ghadjar
Journal:  Radiat Oncol       Date:  2017-08-23       Impact factor: 3.481

4.  Intensity-modulated radiotherapy for prostate cancer with seminal vesicle involvement (T3b): A multicentric retrospective analysis.

Authors:  Flora Goupy; Stéphane Supiot; David Pasquier; Igor Latorzeff; Ulrike Schick; Erik Monpetit; Geoffrey Martinage; Chloé Hervé; Bernadette Le Proust; Joel Castelli; Renaud de Crevoisier
Journal:  PLoS One       Date:  2019-01-25       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.